arrow
S

Stephen Poor

Novartis
H指数:14
被引数:596

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperreflective Foci Contiguous With the Retinal Pigment Epithelium Associated With Visual Function in Aging, Early, and Intermediate Age-Related Macular Degeneration: MACUSTAR Study Report

与视网膜色素上皮层相邻的高反射焦点与老年性、早期和中期年龄相关性黄斑变性中的视功能相关:MACUSTAR研究报告

2026-05-010
OA
Patient-reported vision impairment in low luminance relates to visual function in age-related macular degeneration: A MACUSTAR study report

低亮度下患者报告的视力障碍与年龄相关性黄斑变性患者的视功能有关:MACUSTAR研究报告

2025-10-090
OA
Complement factor B is critical for sub-RPE deposit accumulation in a model of Doyne honeycomb retinal dystrophy with features of age-related macular degeneration
2022-08-098
OAAI
Artificial intelligence-based strategies to identify patient populations and advance analysis in age-related macular degeneration clinical trials
2022-07-016
OAAI
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration
2022-07-0112
OAAI
A proteogenomic signature of age-related macular degeneration in blood
2022-06-1318
OAAI
The Discovery of N-(1-Methy1-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration
2018-02-0532
PREAI
Long-acting protein drugs for the treatment of ocular diseases

治疗眼部疾病的长效蛋白药物

2017-03-2344
OAAI
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
2015-11-3031
OAAI